Merck agrees to buy biopharma firm OncoImmune for $425m
With this deal, Merck will add OncoImunne’s Covid-19 related clinical programmes to its suite. Credit: ONCOIMMUNE.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
